drugset
drugset / Trial / NCT05475834

Study to Investigate the Mass Balance and Biotransformation of SIM0417 in Healthy Adult Chinese Male Participants

NCT05475834 ↗

Phase 1 Completed 6 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a non-randomized, open-label, single-dose, Phase I clinical study to evaluate the mass balance and biotransformation, safety and tolerability of SIM0417 in healthy Chinese adult male subjects following a single oral administration of SIM0417 in combination with ritonavir.

Timeline

Start
2022-07-21
Primary completion
2022-08-07
Completion
2022-08-07

Drugs

EvaluationDrugModalityDoseRoute
Subject simnotrelvir Small molecule 750 mg Oral

Indications

No indication recorded.